{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T13:06:52Z","timestamp":1778332012226,"version":"3.51.4"},"reference-count":95,"publisher":"Siapec Servizi Srl","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathologica"],"DOI":"10.32074\/1591-951x-166","type":"journal-article","created":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T13:39:00Z","timestamp":1611754740000},"page":"166-185","source":"Crossref","is-referenced-by-count":143,"title":["Precancerous lesions of the stomach, gastric cancer and hereditary gastric cancer syndromes"],"prefix":"10.32074","volume":"112","author":[{"given":"Irene","family":"Gullo","sequence":"first","affiliation":[]},{"given":"Federica","family":"Grillo","sequence":"additional","affiliation":[]},{"given":"Luca","family":"Mastracci","sequence":"additional","affiliation":[]},{"given":"Alessandro","family":"Vanoli","sequence":"additional","affiliation":[]},{"given":"Fatima","family":"Carneiro","sequence":"additional","affiliation":[]},{"given":"Luca","family":"Saragoni","sequence":"additional","affiliation":[]},{"given":"Francesco","family":"Limarzi","sequence":"additional","affiliation":[]},{"given":"Jacopo","family":"Ferro","sequence":"additional","affiliation":[]},{"given":"Paola","family":"Parente","sequence":"additional","affiliation":[]},{"given":"Matteo","family":"Fassan","sequence":"additional","affiliation":[]}],"member":"21774","published-online":{"date-parts":[[2020,9]]},"reference":[{"key":"10.32074\/1591-951X-166_ref1","doi-asserted-by":"crossref","unstructured":"Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424. https:\/\/doi.org\/10.3322\/caac.21492","DOI":"10.3322\/caac.21492"},{"key":"10.32074\/1591-951X-166_ref2","doi-asserted-by":"crossref","unstructured":"Gullo I, Carneiro F, Oliveira C, et al. Heterogeneity in gastric cancer: From pure morphology to molecular classifications. Pathobiology 2018;85:50-63. https:\/\/doi.org\/10.1159\/000473881","DOI":"10.1159\/000473881"},{"key":"10.32074\/1591-951X-166_ref3","doi-asserted-by":"crossref","unstructured":"Eusebi LH, Telese A, Marasco G, et al. Gastric cancer prevention strategies: A global perspective. J Gastroenterol Hepatol 2020. Online ahead of print. https:\/\/doi.org\/10.1111\/jgh.15037","DOI":"10.1111\/jgh.15037"},{"key":"10.32074\/1591-951X-166_ref4","doi-asserted-by":"crossref","unstructured":"Fukayama M, Abe H, Kunita A, et al. Thirty years of epstein-barr virus-associated gastric carcinoma. Virchows Arch 2020;476;353-5. https:\/\/doi.org\/10.1007\/s00428-019-02724-4","DOI":"10.1007\/s00428-019-02724-4"},{"key":"10.32074\/1591-951X-166_ref5","doi-asserted-by":"crossref","unstructured":"Sanduleanu S, Jonkers D, De Bruine A, et al. Non-helicobacter pylori bacterial flora during acid-suppressive therapy: differential findings in gastric juice and gastric mucosa. Aliment Pharmacol Ther 2001;15;379-88. https:\/\/doi.org\/10.1046\/j.1365-2036.2001.00888.x","DOI":"10.1046\/j.1365-2036.2001.00888.x"},{"key":"10.32074\/1591-951X-166_ref6","doi-asserted-by":"crossref","unstructured":"Spoto CPE, Gullo I, Carneiro F, et al. Hereditary gastrointestinal carcinomas and their precursors: An algorithm for genetic testing. Semin Diagn Pathol 2018;35;170-83. https:\/\/doi.org\/10.1053\/j.semdp.2018.01.004","DOI":"10.1053\/j.semdp.2018.01.004"},{"key":"10.32074\/1591-951X-166_ref7","doi-asserted-by":"crossref","unstructured":"van der Post RS, Carneiro F. Emerging concepts in gastric neoplasia: Heritable gastric cancers and polyposis disorders. Surg Pathol Clin 2017;10;931-45. https:\/\/doi.org\/10.1016\/j.path.2017.07.011","DOI":"10.1016\/j.path.2017.07.011"},{"key":"10.32074\/1591-951X-166_ref8","unstructured":"Correa P. Human gastric carcinogenesis: a multistep and multifactorial process--first american cancer society award lecture on cancer epidemiology and prevention. Cancer Res 1992;52;6735-40."},{"key":"10.32074\/1591-951X-166_ref9","doi-asserted-by":"crossref","unstructured":"Plummer M, Franceschi S, Vignat J, et al. Global burden of gastric cancer attributable to helicobacter pylori. Int J Cancer 2015;136;487-90. https:\/\/doi.org\/10.1002\/ijc.28999","DOI":"10.1002\/ijc.28999"},{"key":"10.32074\/1591-951X-166_ref10","doi-asserted-by":"crossref","unstructured":"Polk DB, Peek RM Jr. Helicobacter pylori: gastric cancer and beyond. Nat Rev Cancer 2010;10;403-14. https:\/\/doi.org\/10.1038\/nrc2857","DOI":"10.1038\/nrc2857"},{"key":"10.32074\/1591-951X-166_ref11","doi-asserted-by":"crossref","unstructured":"Ferreira RM, Machado JC, Figueiredo C. Clinical relevance of helicobacter pylori vaca and caga genotypes in gastric carcinoma. Best Pract Res Clin Gastroenterol 2014;28;1003-15. https:\/\/doi.org\/10.1016\/j.bpg.2014.09.004","DOI":"10.1016\/j.bpg.2014.09.004"},{"key":"10.32074\/1591-951X-166_ref12","doi-asserted-by":"crossref","unstructured":"Persson C, Canedo P, Machado JC, et al. Polymorphisms in inflammatory response genes and their association with gastric cancer: a huge systematic review and meta-analyses. Am J Epidemiol 2011;173;259-70. https:\/\/doi.org\/10.1093\/aje\/kwq370","DOI":"10.1093\/aje\/kwq370"},{"key":"10.32074\/1591-951X-166_ref13","doi-asserted-by":"crossref","unstructured":"Mahmud N, Stashek K, Katona BW, et al. The incidence of neoplasia in patients with autoimmune metaplastic atrophic gastritis: a renewed call for surveillance. Ann Gastroenterol 2019;32;67-72. https:\/\/doi.org\/10.20524\/aog.2018.0325","DOI":"10.20524\/aog.2018.0325"},{"key":"10.32074\/1591-951X-166_ref14","doi-asserted-by":"crossref","unstructured":"Sipponen P, Price AB. The Sydney system for classification of gastritis 20 years ago. J Gastroenterol Hepatol 2011;26 Suppl 1;31-4. https:\/\/doi.org\/10.1111\/j.1440-1746.2010.06536.x","DOI":"10.1111\/j.1440-1746.2010.06536.x"},{"key":"10.32074\/1591-951X-166_ref15","doi-asserted-by":"crossref","unstructured":"Meining A, Bayerdorffer E, Muller P, et al. Gastric carcinoma risk index in patients infected with helicobacter pylori. Virchows Arch 1998;432;311-4. https:\/\/doi.org\/10.1007\/s004280050171","DOI":"10.1007\/s004280050171"},{"key":"10.32074\/1591-951X-166_ref16","doi-asserted-by":"crossref","unstructured":"Rugge M, Meggio A, Pennelli G, et al. Gastritis staging in clinical practice: the olga staging system. Gut 2007;56;631-6. https:\/\/doi.org\/gut.2006.106666 [pii]10.1136\/gut.2006.106666","DOI":"10.1136\/gut.2006.106666"},{"key":"10.32074\/1591-951X-166_ref17","doi-asserted-by":"crossref","unstructured":"Pimentel-Nunes P, Lib\u00e2nio D, Marcos-Pinto R, et al. Management of epithelial precancerous conditions and lesions in the stomach (maps ii): European society of gastrointestinal endoscopy (esge), european helicobacter and microbiota study group (ehmsg), european society of pathology (esp), and sociedade portuguesa de endoscopia digestiva (sped) guideline update 2019. Endoscopy 2019;51;365-88. https:\/\/doi.org\/10.1055\/a-0859-1883","DOI":"10.1055\/a-0859-1883"},{"key":"10.32074\/1591-951X-166_ref18","doi-asserted-by":"crossref","unstructured":"Spechler SJ, Merchant JL, Wang TC, et al. A summary of the 2016 James W. Freston conference of the american gastroenterological association: Intestinal metaplasia in the esophagus and stomach: origins, differences, similarities and significance. Gastroenterology 2017;153;e6-e13. https:\/\/doi.org\/10.1053\/j.gastro.2017.05.050","DOI":"10.1053\/j.gastro.2017.05.050"},{"key":"10.32074\/1591-951X-166_ref19","unstructured":"Reis CA, David L, Correa P, et al. Intestinal metaplasia of human stomach displays distinct patterns of mucin (muc1, muc2, muc5ac, and muc6) expression. Cancer Res 1999;59;1003-7."},{"key":"10.32074\/1591-951X-166_ref20","doi-asserted-by":"crossref","unstructured":"Leung WK, Lin SR, Ching JY, et al. Factors predicting progression of gastric intestinal metaplasia: Results of a randomised trial on helicobacter pylori eradication. Gut 2004;53;1244-9. https:\/\/doi.org\/10.1136\/gut.2003.034629","DOI":"10.1136\/gut.2003.034629"},{"key":"10.32074\/1591-951X-166_ref21","doi-asserted-by":"crossref","unstructured":"Goldenring JR, Nam KT, Wang TC, et al. Spasmolytic polypeptide-expressing metaplasia and intestinal metaplasia: time for reevaluation of metaplasias and the origins of gastric cancer. Gastroenterology 2010;138;2207-2210, 2210.e2201. https:\/\/doi.org\/10.1053\/j.gastro.2010.04.023","DOI":"10.1053\/j.gastro.2010.04.023"},{"key":"10.32074\/1591-951X-166_ref22","doi-asserted-by":"crossref","unstructured":"Valente P, Garrido M, Gullo I, et al. Epithelial dysplasia of the stomach with gastric immunophenotype shows features of biological aggressiveness. Gastric Cancer 2015;18;720-8. https:\/\/doi.org\/10.1007\/s10120-014-0416-5","DOI":"10.1007\/s10120-014-0416-5"},{"key":"10.32074\/1591-951X-166_ref23","unstructured":"WHO Classification of tumors. Digestive system tumors. Tumors of the stomach. WHO Classification of Tumors Editorial Board. 5th Ed. Lyon: IARC press 2019, pp. 59-110."},{"key":"10.32074\/1591-951X-166_ref24","doi-asserted-by":"crossref","unstructured":"Kim A, Ahn SJ, Park DY, et al. Gastric crypt dysplasia: a distinct subtype of gastric dysplasia with characteristic endoscopic features and immunophenotypic and biological anomalies. Histopathology 2016;68;843-9. https:\/\/doi.org\/10.1111\/his.12860","DOI":"10.1111\/his.12860"},{"key":"10.32074\/1591-951X-166_ref25","doi-asserted-by":"crossref","unstructured":"Hackeng WM, Montgomery EA, Giardiello FM, et al. Morphology and genetics of pyloric gland adenomas in familial adenomatous polyposis. Histopathology 2017;70:549-57. https:\/\/doi.org\/10.1111\/his.13105","DOI":"10.1111\/his.13105"},{"key":"10.32074\/1591-951X-166_ref26","doi-asserted-by":"crossref","unstructured":"Brosens LA, Wood LD, Offerhaus GJ, et al. Pathology and genetics of syndromic gastric polyps. Int J Surg Pathol 2016;24;185-99. https:\/\/doi.org\/10.1177\/1066896915620013","DOI":"10.1177\/1066896915620013"},{"key":"10.32074\/1591-951X-166_ref27","doi-asserted-by":"crossref","unstructured":"Benedict MA, Lauwers GY, Jain D. Gastric adenocarcinoma of the fundic gland type: Update and literature review. Am J Clin Pathol 2018;149;461-73. https:\/\/doi.org\/10.1093\/ajcp\/aqy019","DOI":"10.1093\/ajcp\/aqy019"},{"key":"10.32074\/1591-951X-166_ref28","doi-asserted-by":"crossref","unstructured":"Ahn JY, Son DH, Choi KD, et al. Neoplasms arising in large gastric hyperplastic polyps: Endoscopic and pathologic features. Gastrointest Endosc 2014;80;1005-1013.e1002. https:\/\/doi.org\/10.1016\/j.gie.2014.04.020","DOI":"10.1016\/j.gie.2014.04.020"},{"key":"10.32074\/1591-951X-166_ref29","doi-asserted-by":"crossref","unstructured":"Takayama Y, Ono Y, Mizukami Y, et al. Comparative genome-wide analysis of gastric adenocarcinomas with hyperplastic polyp components. Virchows Arch 2019;475;383-9. https:\/\/doi.org\/10.1007\/s00428-019-02592-y","DOI":"10.1007\/s00428-019-02592-y"},{"key":"10.32074\/1591-951X-166_ref30","doi-asserted-by":"crossref","unstructured":"Carmack SW, Genta RM, Schuler CM, et al. The current spectrum of gastric polyps: A 1-year national study of over 120,000 patients. Am J Gastroenterol 2009;104;1524-32. https:\/\/doi.org\/10.1038\/ajg.2009.139","DOI":"10.1038\/ajg.2009.139"},{"key":"10.32074\/1591-951X-166_ref31","doi-asserted-by":"crossref","unstructured":"Abraham SC, Nobukawa B, Giardiello FM, et al. Fundic gland polyps in familial adenomatous polyposis: neoplasms with frequent somatic adenomatous polyposis coli gene alterations. Am J Pathol 2000;157;747-54. https:\/\/doi.org\/10.1016\/s0002-9440(10)64588-9","DOI":"10.1016\/S0002-9440(10)64588-9"},{"key":"10.32074\/1591-951X-166_ref32","doi-asserted-by":"crossref","unstructured":"Hamashima C. Cancer screening guidelines and policy making: 15 years of experience in cancer screening guideline development in japan. Jpn J Clin Oncol 2018;48;278-86. https:\/\/doi.org\/10.1093\/jjco\/hyx190","DOI":"10.1093\/jjco\/hyx190"},{"key":"10.32074\/1591-951X-166_ref33","doi-asserted-by":"crossref","unstructured":"Teh JL, Shabbir A, Yuen S, et al. Recent advances in diagnostic upper endoscopy. World J Gastroenterol 2020;26;433-47. https:\/\/doi.org\/10.3748\/wjg.v26.i4.433","DOI":"10.3748\/wjg.v26.i4.433"},{"key":"10.32074\/1591-951X-166_ref34","doi-asserted-by":"crossref","unstructured":"Tsukuma H, Mishima T, Oshima A. Prospective study of \u201cearly\u201d gastric cancer. Int J Cancer 1983;31;421-26.","DOI":"10.1002\/ijc.2910310405"},{"key":"10.32074\/1591-951X-166_ref35","doi-asserted-by":"crossref","unstructured":"Pimentel-Nunes P, Dinis-Ribeiro M, Ponchon T, et al. Endoscopic submucosal dissection: European society of gastrointestinal endoscopy (esge) guideline. Endoscopy 2015;47;829-54. https:\/\/doi.org\/10.1055\/s-0034-1392882","DOI":"10.1055\/s-0034-1392882"},{"key":"10.32074\/1591-951X-166_ref36","doi-asserted-by":"crossref","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of her2-positive advanced gastric or gastro-oesophageal junction cancer (toga): a phase 3, open-label, randomised controlled trial. Lancet 2010;376;687-97. https:\/\/doi.org\/10.1016\/s0140-6736(10)61121-x","DOI":"10.1016\/S0140-6736(10)61121-X"},{"key":"10.32074\/1591-951X-166_ref37","doi-asserted-by":"crossref","unstructured":"Fuchs CS, Tabernero J, Tomasek J, et al. Biomarker analyses in regard gastric\/gej carcinoma patients treated with vegfr2-targeted antibody ramucirumab. Br J Cancer 2016;115;974-82. https:\/\/doi.org\/10.1038\/bjc.2016.293","DOI":"10.1038\/bjc.2016.293"},{"key":"10.32074\/1591-951X-166_ref38","doi-asserted-by":"crossref","unstructured":"Smyth EC, Verheij M, Allum W, et al. Gastric cancer: esmo clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016;27;v38-v49. https:\/\/doi.org\/10.1093\/annonc\/mdw350","DOI":"10.1093\/annonc\/mdw350"},{"key":"10.32074\/1591-951X-166_ref39","doi-asserted-by":"crossref","unstructured":"Grillo F, Fassan M, Sarocchi F, et al. HER2 heterogeneity in gastric\/gastroesophageal cancers: from benchside to practice. World J Gastroenterol 2016;22:5879-87. https:\/\/doi.org\/10.3748\/wjg.v22.i26.5879","DOI":"10.3748\/wjg.v22.i26.5879"},{"key":"10.32074\/1591-951X-166_ref40","doi-asserted-by":"crossref","unstructured":"Grillo F, Fassan M, Ceccaroli C, et al. The reliability of endoscopic biopsies in assessing HER2 status in gastric and gastroesophageal junction cancer: a study comparing biopsies with surgical samples. Transl Oncol 2013;6:10-6. https:\/\/doi.org\/10.1593\/tlo.12334","DOI":"10.1593\/tlo.12334"},{"key":"10.32074\/1591-951X-166_ref41","doi-asserted-by":"crossref","unstructured":"Gullo I, Grillo F, Molinaro L, et al. Minimum biopsy set for HER2 evaluation in gastric and gastro-esophageal junction cancer. Endosc Int Open 2015;3:E165-70. https:\/\/doi.org\/10.1055\/s-0034-1391359","DOI":"10.1055\/s-0034-1391359"},{"key":"10.32074\/1591-951X-166_ref42","doi-asserted-by":"crossref","unstructured":"Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to pd-1 blockade. Science 2017;357;409-13. https:\/\/doi.org\/10.1126\/science.aan6733","DOI":"10.1126\/science.aan6733"},{"key":"10.32074\/1591-951X-166_ref43","doi-asserted-by":"crossref","unstructured":"Sohn BH, Hwang JE, Jang HJ, et al. Clinical significance of four molecular subtypes of gastric cancer identified by the cancer genome atlas project. Clin Cancer Res 2017. https:\/\/doi.org\/10.1158\/1078-0432.ccr-16-2211","DOI":"10.1158\/1078-0432.CCR-16-2211"},{"key":"10.32074\/1591-951X-166_ref44","doi-asserted-by":"crossref","unstructured":"Kulangara K, Zhang N, Corigliano E, et al. Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer. Arch Pathol Lab Med 2019;143:330-7. https:\/\/doi.org\/10.5858\/arpa.2018-0043-OA","DOI":"10.5858\/arpa.2018-0043-OA"},{"key":"10.32074\/1591-951X-166_ref45","doi-asserted-by":"crossref","unstructured":"Topalian SL, Taube JM, Anders RA, et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 2016;16;275-87. https:\/\/doi.org\/10.1038\/nrc.2016.36","DOI":"10.1038\/nrc.2016.36"},{"key":"10.32074\/1591-951X-166_ref46","doi-asserted-by":"crossref","unstructured":"Sano T, Coit DG, Kim HH, et al. Proposal of a new stage grouping of gastric cancer for tnm classification: International gastric cancer association staging project. Gastric Cancer 2017;20;217-25. https:\/\/doi.org\/10.1007\/s10120-016-0601-9","DOI":"10.1007\/s10120-016-0601-9"},{"key":"10.32074\/1591-951X-166_ref47","doi-asserted-by":"crossref","unstructured":"Solcia E, Klersy C, Mastracci L, et al. A combined histologic and molecular approach identifies three groups of gastric cancer with different prognosis. Virchows Arch 2009;455:197-211. https:\/\/doi.org\/10.1007\/s00428-009-0813-z","DOI":"10.1007\/s00428-009-0813-z"},{"key":"10.32074\/1591-951X-166_ref48","doi-asserted-by":"crossref","unstructured":"Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965;64;31-49.","DOI":"10.1111\/apm.1965.64.1.31"},{"key":"10.32074\/1591-951X-166_ref49","doi-asserted-by":"crossref","unstructured":"Zheng HC, Li XH, Hara T, et al. Mixed-type gastric carcinomas exhibit more aggressive features and indicate the histogenesis of carcinomas. Virchows Arch 2008;452;525-34. https:\/\/doi.org\/10.1007\/s00428-007-0572-7","DOI":"10.1007\/s00428-007-0572-7"},{"key":"10.32074\/1591-951X-166_ref50","doi-asserted-by":"crossref","unstructured":"Carneiro F. Classification of gastric carcinomas. Current Diagnostic Pathology 1997;4;51-9.","DOI":"10.1016\/S0968-6053(97)80008-7"},{"key":"10.32074\/1591-951X-166_ref51","doi-asserted-by":"crossref","unstructured":"Kwon CH, Kim YK, Lee S, et al. Gastric poorly cohesive carcinoma: a correlative study of mutational signatures and prognostic significance based on histopathological subtypes. Histopathology 2018;72;556-68. https:\/\/doi.org\/10.1111\/his.13383","DOI":"10.1111\/his.13383"},{"key":"10.32074\/1591-951X-166_ref52","unstructured":"Japanese gastric cancer association. Japanese classification of gastric carcinoma. The 15th edition. 2017. Isbn: 978-4-307-20375-3."},{"key":"10.32074\/1591-951X-166_ref53","unstructured":"Saragoni L. Upgrading the definition of early gastric cancer: better staging means more appropriate treatment. Cancer Biol Med 2015;12:355-61. https:\/\/doi.org\/10.7497\/j.issn.2095-3941.2015.0054"},{"key":"10.32074\/1591-951X-166_ref54","doi-asserted-by":"crossref","unstructured":"Saragoni L, Scarpi E, Ravaioli A, et al. Early gastric cancer: clinical behavior and treatment options. Results of an Italian Multicenter Study on behalf of the Italian Gastric Cancer Research Group (GIRCG). Oncologist 2018;23:852-8. https:\/\/doi.org\/10.1634\/theoncologist.2017-0488","DOI":"10.1634\/theoncologist.2017-0488"},{"key":"10.32074\/1591-951X-166_ref55","doi-asserted-by":"crossref","unstructured":"Kodama Y, Inokuchi K, Soejima K, et al. Growth patterns and prognosis in early gastric cancer. Superficially spreading and penetrating growth types. Cancer 1983;51:320-6.","DOI":"10.1002\/1097-0142(19830115)51:2<320::AID-CNCR2820510226>3.0.CO;2-#"},{"key":"10.32074\/1591-951X-166_ref56","doi-asserted-by":"crossref","unstructured":"Saragoni L, Morgagni P, Gardni A et el. Early gastric cancer: diagnosis, staging, and clinical impact. Evaluation of 530 patients. New elements for an updated definition and classification. Gastric Cancer 2013;16:549-54. https:\/\/doi.org\/10.1007\/s10120-013-0233-2","DOI":"10.1007\/s10120-013-0233-2"},{"key":"10.32074\/1591-951X-166_ref57","doi-asserted-by":"crossref","unstructured":"Lei Z, Tan IB, Das K, et al. Identification of molecular subtypes of gastric cancer with different responses to pi3-kinase inhibitors and 5-fluorouracil. Gastroenterology 2013;145;554-65. https:\/\/doi.org\/10.1053\/j.gastro.2013.05.010","DOI":"10.1053\/j.gastro.2013.05.010"},{"key":"10.32074\/1591-951X-166_ref58","doi-asserted-by":"crossref","unstructured":"TCGA. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014;513;202-9. https:\/\/doi.org\/10.1038\/nature13480","DOI":"10.1038\/nature13480"},{"key":"10.32074\/1591-951X-166_ref59","doi-asserted-by":"crossref","unstructured":"Cristescu R, Lee J, Nebozhyn M, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med 2015;21;449-56. https:\/\/doi.org\/10.1038\/nm.3850","DOI":"10.1038\/nm.3850"},{"key":"10.32074\/1591-951X-166_ref60","doi-asserted-by":"crossref","unstructured":"Song HJ, Kim KM. Pathology of epstein-barr virus-associated gastric carcinoma and its relationship to prognosis. Gut Liver 2011;5;143-8. https:\/\/doi.org\/10.5009\/gnl.2011.5.2.143","DOI":"10.5009\/gnl.2011.5.2.143"},{"key":"10.32074\/1591-951X-166_ref61","doi-asserted-by":"crossref","unstructured":"Chiaravalli AM, Cornaggia M, Furlan D, et al. The role of histological investigation in prognostic evaluation of advanced gastric cancer. Analysis of histological structure and molecular changes compared with invasive pattern and stage. Virchows Arch 2001;439;158-69. https:\/\/doi.org\/10.1007\/s004280100441","DOI":"10.1007\/s004280100441"},{"key":"10.32074\/1591-951X-166_ref62","doi-asserted-by":"crossref","unstructured":"Gullo I, Carvalho J, Martins D, et al. The transcriptomic landscape of gastric cancer: Insights into epstein-barr virus infected and microsatellite unstable tumors. Int J Mol Sci 2018;19. https:\/\/doi.org\/10.3390\/ijms19072079","DOI":"10.3390\/ijms19072079"},{"key":"10.32074\/1591-951X-166_ref63","doi-asserted-by":"crossref","unstructured":"Setia N, Agoston AT, Han HS, et al. A protein and mrna expression-based classification of gastric cancer. Mod Pathol 2016;29;772-84. https:\/\/doi.org\/10.1038\/modpathol.2016.55","DOI":"10.1038\/modpathol.2016.55"},{"key":"10.32074\/1591-951X-166_ref64","doi-asserted-by":"crossref","unstructured":"Ahn S, Lee SJ, Kim Y, et al. High-throughput protein and mrna expression-based classification of gastric cancers can identify clinically distinct subtypes, concordant with recent molecular classifications. Am J Surg Pathol 2017;41;106-15. https:\/\/doi.org\/10.1097\/pas.0000000000000756","DOI":"10.1097\/PAS.0000000000000756"},{"key":"10.32074\/1591-951X-166_ref65","doi-asserted-by":"crossref","unstructured":"Machicado J, Shroff J, Quesada A, et al. Gastritis cystica profunda: endoscopic ultrasound findings and review of the literature. Endosc Ultrasound 2014;3;131-4. https:\/\/doi.org\/10.4103\/2303-9027.131041","DOI":"10.4103\/2303-9027.131041"},{"key":"10.32074\/1591-951X-166_ref66","doi-asserted-by":"crossref","unstructured":"Choi MG, Jeong JY, Kim KM, et al. Clinical significance of gastritis cystica profunda and its association with epstein-barr virus in gastric cancer. Cancer 2012;118;5227-33. https:\/\/doi.org\/10.1002\/cncr.27541","DOI":"10.1002\/cncr.27541"},{"key":"10.32074\/1591-951X-166_ref67","doi-asserted-by":"crossref","unstructured":"67\tAgaimy A, Rau TT, Hartmann A, et al. SMARCB1 (INI1)-negative rhabdoid carcinomas of the gastrointestinal tract: clinicopathologic and molecular study of a highly aggressive variant with literature review. Am J Surg Pathol 2014;38:910-20. https:\/\/doi.org\/10.1097\/PAS.0000000000000173","DOI":"10.1097\/PAS.0000000000000173"},{"key":"10.32074\/1591-951X-166_ref68","doi-asserted-by":"crossref","unstructured":"Gullo I, Oliveira P, Athelogou M, et al. New insights into the inflamed tumor immune microenvironment of gastric cancer with lymphoid stroma: from morphology and digital analysis to gene expression. Gastric Cancer 2019;22;77-90. https:\/\/doi.org\/10.1007\/s10120-018-0836-8","DOI":"10.1007\/s10120-018-0836-8"},{"key":"10.32074\/1591-951X-166_ref69","doi-asserted-by":"crossref","unstructured":"Yamazawa S, Ushiku T, Shinozaki-Ushiku A, et al. Gastric cancer with primitive enterocyte phenotype: An aggressive subgroup of intestinal-type adenocarcinoma. Am J Surg Pathol 2017;41;989-97. https:\/\/doi.org\/10.1097\/pas.0000000000000869","DOI":"10.1097\/PAS.0000000000000869"},{"key":"10.32074\/1591-951X-166_ref70","doi-asserted-by":"crossref","unstructured":"Ushiku T, Uozaki H, Shinozaki A, et al. Glypican 3-expressing gastric carcinoma: distinct subgroup unifying hepatoid, clear-cell, and alpha-fetoprotein-producing gastric carcinomas. Cancer Sci 2009;100;626-32. https:\/\/doi.org\/10.1111\/j.1349-7006.2009.01108.x","DOI":"10.1111\/j.1349-7006.2009.01108.x"},{"key":"10.32074\/1591-951X-166_ref71","doi-asserted-by":"crossref","unstructured":"Ushiku T, Shinozaki A, Shibahara J, et al. Sall4 represents fetal gut differentiation of gastric cancer, and is diagnostically useful in distinguishing hepatoid gastric carcinoma from hepatocellular carcinoma. Am J Surg Pathol 2010;34;533-40. https:\/\/doi.org\/10.1097\/PAS.0b013e3181d1dcdd","DOI":"10.1097\/PAS.0b013e3181d1dcdd"},{"key":"10.32074\/1591-951X-166_ref72","doi-asserted-by":"crossref","unstructured":"Mochizuki K, Kawai M, Odate T, et al. Smarcb1\/ini1 is diagnostically useful in distinguishing \u03b1-fetoprotein-producing gastric carcinoma from hepatocellular carcinoma. Anticancer Res 2018;38;6865-8. https:\/\/doi.org\/10.21873\/anticanres.13061","DOI":"10.21873\/anticanres.13061"},{"key":"10.32074\/1591-951X-166_ref73","doi-asserted-by":"crossref","unstructured":"Roh JH, Srivastava A, Lauwers GY et al. Micropapillary carcinoma of stomach: a clinicopathologic and immunohistochemical study of 11 cases. Am J Surg Pathol 2010;34:1139-46. https:\/\/doi.org\/10.1097\/PAS.0b013e3181e7043b","DOI":"10.1097\/PAS.0b013e3181e7043b"},{"key":"10.32074\/1591-951X-166_ref74","doi-asserted-by":"crossref","unstructured":"Oliveira C, Pinheiro H, Figueiredo J, et al. Familial gastric cancer: genetic susceptibility, pathology, and implications for management. Lancet Oncol 2015;16;e60-70. https:\/\/doi.org\/10.1016\/s1470-2045(14)71016-2","DOI":"10.1016\/S1470-2045(14)71016-2"},{"key":"10.32074\/1591-951X-166_ref75","doi-asserted-by":"crossref","unstructured":"Van der Post RS, Vogelaar IP, Carneiro F, et al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline cdh1 mutation carriers. J Med Genet 2015;52:361-74. https:\/\/doi.org\/10.1136\/jmedgenet-2015-103094","DOI":"10.1136\/jmedgenet-2015-103094"},{"key":"10.32074\/1591-951X-166_ref76","doi-asserted-by":"crossref","unstructured":"Blair VR MM, Carneiro F, Coit DG, et al. Hereditary diffuse gastric cancer: updated clinical practice guidelines. Lancet Oncol 2020;21:e386-e97. https:\/\/doi.org\/10.1016\/S1470-2045(20)30219-9","DOI":"10.1016\/S1470-2045(20)30219-9"},{"key":"10.32074\/1591-951X-166_ref77","doi-asserted-by":"crossref","unstructured":"Roberts ME, Ranola JMO, Marshall ML, et al. Comparison of cdh1 penetrance estimates in clinically ascertained families vs families ascertained for multiple gastric cancers. JAMA Oncol 2019;5;1325-31. https:\/\/doi.org\/10.1001\/jamaoncol.2019.1208","DOI":"10.1001\/jamaoncol.2019.1208"},{"key":"10.32074\/1591-951X-166_ref78","doi-asserted-by":"crossref","unstructured":"Gullo I, Devezas V, Baptista M, et al. Phenotypic heterogeneity of hereditary diffuse gastric cancer: report of a family with early-onset disease. Gastrointest Endosc 2018;87;1566-75. https:\/\/doi.org\/10.1016\/j.gie.2018.02.008","DOI":"10.1016\/j.gie.2018.02.008"},{"key":"10.32074\/1591-951X-166_ref79","doi-asserted-by":"crossref","unstructured":"Mi EZ, Mi EZ, di Pietro M, et al. Comparative study of endoscopic surveillance in hereditary diffuse gastric cancer according to cdh1 mutation status. Gastrointest Endosc 2017. https:\/\/doi.org\/10.1016\/j.gie.2017.06.028","DOI":"10.1016\/j.gie.2017.06.028"},{"key":"10.32074\/1591-951X-166_ref80","doi-asserted-by":"crossref","unstructured":"Rocha JP, Gullo I, Wen X, et al. Pathological features of total gastrectomy specimens from asymptomatic hereditary diffuse gastric cancer patients and implications for clinical management. Histopathology 2018;73;878-86. https:\/\/doi.org\/10.1111\/his.13715","DOI":"10.1111\/his.13715"},{"key":"10.32074\/1591-951X-166_ref81","doi-asserted-by":"crossref","unstructured":"Huntsman DG, Carneiro F, Lewis FR, et al. Early gastric cancer in young, asymptomatic carriers of germ-line e-cadherin mutations. N Engl J Med 2001;344;1904-9. https:\/\/doi.org\/10.1056\/nejm200106213442504","DOI":"10.1056\/NEJM200106213442504"},{"key":"10.32074\/1591-951X-166_ref82","doi-asserted-by":"crossref","unstructured":"Carneiro F, Huntsman DG, Smyrk TC, et al. Model of the early development of diffuse gastric cancer in e-cadherin mutation carriers and its implications for patient screening. J Pathol 2004;203;681-7. https:\/\/doi.org\/10.1002\/path.1564","DOI":"10.1002\/path.1564"},{"key":"10.32074\/1591-951X-166_ref83","doi-asserted-by":"crossref","unstructured":"van der Post RS, Gullo I, Oliveira C, et al. Histopathological, molecular, and genetic profile of hereditary diffuse gastric cancer: current knowledge and challenges for the future. Adv Exp Med Biol 2016;908;371-91. https:\/\/doi.org\/10.1007\/978-3-319-41388-4_18","DOI":"10.1007\/978-3-319-41388-4_18"},{"key":"10.32074\/1591-951X-166_ref84","doi-asserted-by":"crossref","unstructured":"Lee HE, Smyrk TC, Zhang L. Histologic and immunohistochemical differences between hereditary and sporadic diffuse gastric carcinoma. Hum Pathol 2018;74;64-72. https:\/\/doi.org\/10.1016\/j.humpath.2017.12.023","DOI":"10.1016\/j.humpath.2017.12.023"},{"key":"10.32074\/1591-951X-166_ref85","doi-asserted-by":"crossref","unstructured":"Mahmud N, Ford JM, Longacre TA, et al. Metastatic lobular breast carcinoma mimicking primary signet ring adenocarcinoma in a patient with a suspected cdh1 mutation. J Clin Oncol 2015;33;e19-21. https:\/\/doi.org\/10.1200\/jco.2013.49.1159","DOI":"10.1200\/JCO.2013.49.1159"},{"key":"10.32074\/1591-951X-166_ref86","doi-asserted-by":"crossref","unstructured":"van der Post RS, Bult P, Vogelaar IP, et al. Hnf4a immunohistochemistry facilitates distinction between primary and metastatic breast and gastric carcinoma. Virchows Arch 2014;464;673-9. https:\/\/doi.org\/10.1007\/s00428-014-1574-x","DOI":"10.1007\/s00428-014-1574-x"},{"key":"10.32074\/1591-951X-166_ref87","doi-asserted-by":"crossref","unstructured":"Li J, Woods SL, Healey S, et al. Point mutations in exon 1b of apc reveal gastric adenocarcinoma and proximal polyposis of the stomach as a familial adenomatous polyposis variant. Am J Hum Genet 2016;98;830-42. https:\/\/doi.org\/10.1016\/j.ajhg.2016.03.001","DOI":"10.1016\/j.ajhg.2016.03.001"},{"key":"10.32074\/1591-951X-166_ref88","doi-asserted-by":"crossref","unstructured":"Worthley DL, Phillips KD, Wayte N, et al. Gastric adenocarcinoma and proximal polyposis of the stomach (gapps): a new autosomal dominant syndrome. Gut 2012;61;774-9. https:\/\/doi.org\/10.1136\/gutjnl-2011-300348","DOI":"10.1136\/gutjnl-2011-300348"},{"key":"10.32074\/1591-951X-166_ref89","doi-asserted-by":"crossref","unstructured":"de Boer WB, Ee H, Kumarasinghe MP. Neoplastic lesions of gastric adenocarcinoma and proximal polyposis syndrome (gapps) are gastric phenotype. Am J Surg Pathol 2018;42;1-8. https:\/\/doi.org\/10.1097\/pas.0000000000000924","DOI":"10.1097\/PAS.0000000000000924"},{"key":"10.32074\/1591-951X-166_ref90","unstructured":"Caldas C, Carneiro F, Lynch HT, et al. Familial gastric cancer: overview and guidelines for management. J Med Genet 1999;36;873-80."},{"key":"10.32074\/1591-951X-166_ref91","doi-asserted-by":"crossref","unstructured":"Carvalho J, Oliveira P, Senz J, et al. Redefinition of familial intestinal gastric cancer: Clinical and genetic perspectives. J Med Genet 2020. https:\/\/doi.org\/10.1136\/jmedgenet-2019-106346","DOI":"10.1136\/jmedgenet-2019-106346"},{"key":"10.32074\/1591-951X-166_ref92","doi-asserted-by":"crossref","unstructured":"Zhu Y, Sun Y, Hu S, et al. Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China. BMC Gastroenterol 2017;17:41. https:\/\/doi.org\/10.1186\/s12876-017-0598-5","DOI":"10.1186\/s12876-017-0598-5"},{"key":"10.32074\/1591-951X-166_ref93","doi-asserted-by":"crossref","unstructured":"Fanelli GN, Loupakis F, Smyth E, et al. Pathological tumor regression grade classifications in gastrointestinal cancers: role on patients\u2019 prognosis. Int J Surg Pathol. 2019;27:816-35. https:\/\/doi.org\/10.1177\/1066896919869477","DOI":"10.1177\/1066896919869477"},{"key":"10.32074\/1591-951X-166_ref94","doi-asserted-by":"crossref","unstructured":"Becker K, Mueller JD, Schulmacher C, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 2003;98:1521-30.","DOI":"10.1002\/cncr.11660"},{"key":"10.32074\/1591-951X-166_ref95","doi-asserted-by":"crossref","unstructured":"Tsekrekos A, Detlefsen S, Riddell R, et al. Histopathologic tumor regression grading in patients with gastric carcinoma submitted to neoadjuvant treatment: results of a Delphi survey. Hum Pathol 2019;84:26-34. https:\/\/doi.org\/0.1016\/j.humpath.2018.08.028","DOI":"10.1016\/j.humpath.2018.08.028"}],"container-title":["Pathologica"],"original-title":[],"link":[{"URL":"https:\/\/www.pathologica.it\/article\/view\/166","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T13:25:07Z","timestamp":1730813107000},"score":1,"resource":{"primary":{"URL":"https:\/\/old.pathologica.it\/article\/view\/166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":95,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,9]]}},"URL":"https:\/\/doi.org\/10.32074\/1591-951x-166","relation":{},"ISSN":["1591-951X"],"issn-type":[{"value":"1591-951X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9]]},"article-number":"6"}}